- Home
- APLT vs IMMX Comparison
APLT vs IMMX Comparison
Compare APLT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- IMMX
- Stock Information
- Founded
- APLT 2016
- IMMX 2014
- Country
- APLT United States
- IMMX United States
- Employees
- APLT N/A
- IMMX N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- APLT Health Care
- IMMX Health Care
- Exchange
- APLT Nasdaq
- IMMX Nasdaq
- Market Cap
- APLT 69.0M
- IMMX 65.5M
- IPO Year
- APLT 2019
- IMMX 2021
- Fundamental
- Price
- APLT $0.51
- IMMX $2.19
- Analyst Decision
- APLT Buy
- IMMX Strong Buy
- Analyst Count
- APLT 6
- IMMX 1
- Target Price
- APLT $6.10
- IMMX $7.00
- AVG Volume (30 Days)
- APLT 893.4K
- IMMX 255.8K
- Earning Date
- APLT 08-13-2025
- IMMX 08-08-2025
- Dividend Yield
- APLT N/A
- IMMX N/A
- EPS Growth
- APLT N/A
- IMMX N/A
- EPS
- APLT N/A
- IMMX N/A
- Revenue
- APLT $121,000.00
- IMMX N/A
- Revenue This Year
- APLT $415.60
- IMMX N/A
- Revenue Next Year
- APLT $1,323.96
- IMMX N/A
- P/E Ratio
- APLT N/A
- IMMX N/A
- Revenue Growth
- APLT N/A
- IMMX N/A
- 52 Week Low
- APLT $0.30
- IMMX $1.26
- 52 Week High
- APLT $10.62
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- APLT 61.88
- IMMX 39.38
- Support Level
- APLT $0.47
- IMMX $2.11
- Resistance Level
- APLT $0.53
- IMMX $2.39
- Average True Range (ATR)
- APLT 0.03
- IMMX 0.21
- MACD
- APLT 0.00
- IMMX -0.03
- Stochastic Oscillator
- APLT 83.33
- IMMX 9.52
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.